Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats

Kazuhito Takamura, Kunihiro Tsuchida, Hidenori Miyake, Seiki Tashiro, Hiromu Sugino

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Aims: Activin A is an autocrine inhibitor of cell growth in the liver. The biological activity of activin A is mediated by a heteromeric receptor complex. Follistatin (FS) binds to activin and inhibits its biological effects, and acts as a negative regulator of muscle cells. The role of activin receptors during liver regeneration following a hepatectomy has not been fully assessed. This study investigates the mechanism underlying how activin receptors regulate hepatocyte growth, and the effects of intravenous administration of FS during liver regeneration. Methodology: The expression of both activins and activin receptors in the liver after a 70% partial hepatectomy (HT) was assessed by RT-PCR and immunohistochemistry. FS 315 or 288 was infused for different periods of time based on changes in hepatocyte activin receptor expression after HT. Results: Activin receptor expression peaked between 48 and 72 hours after HT. 72 hours after HT, an injection of FS 315 resulted in a more potent stimulation of DNA synthesis and produced a greater increase in body weight compared with the control rats. Conclusions: The expression of activin receptors after peak DNA synthesis might be a key component in the downregulation of DNA synthesis. Intravenous administration of FS 315 might promote liver regeneration and have anabolic actions.

Original languageEnglish
Pages (from-to)60-66
Number of pages7
JournalHepato-gastroenterology
Volume52
Issue number61
Publication statusPublished - 01-01-2005

Fingerprint

Activin Receptors
Follistatin
Liver Regeneration
Hepatectomy
Activins
Intravenous Administration
Hepatocytes
DNA
Growth Inhibitors
Liver
Muscle Cells
Down-Regulation
Immunohistochemistry
Body Weight
Polymerase Chain Reaction
Injections
Growth

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{d246c5b27b6c4425870f00b1b3f9ce62,
title = "Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats",
abstract = "Background/Aims: Activin A is an autocrine inhibitor of cell growth in the liver. The biological activity of activin A is mediated by a heteromeric receptor complex. Follistatin (FS) binds to activin and inhibits its biological effects, and acts as a negative regulator of muscle cells. The role of activin receptors during liver regeneration following a hepatectomy has not been fully assessed. This study investigates the mechanism underlying how activin receptors regulate hepatocyte growth, and the effects of intravenous administration of FS during liver regeneration. Methodology: The expression of both activins and activin receptors in the liver after a 70{\%} partial hepatectomy (HT) was assessed by RT-PCR and immunohistochemistry. FS 315 or 288 was infused for different periods of time based on changes in hepatocyte activin receptor expression after HT. Results: Activin receptor expression peaked between 48 and 72 hours after HT. 72 hours after HT, an injection of FS 315 resulted in a more potent stimulation of DNA synthesis and produced a greater increase in body weight compared with the control rats. Conclusions: The expression of activin receptors after peak DNA synthesis might be a key component in the downregulation of DNA synthesis. Intravenous administration of FS 315 might promote liver regeneration and have anabolic actions.",
author = "Kazuhito Takamura and Kunihiro Tsuchida and Hidenori Miyake and Seiki Tashiro and Hiromu Sugino",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "52",
pages = "60--66",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "61",

}

Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats. / Takamura, Kazuhito; Tsuchida, Kunihiro; Miyake, Hidenori; Tashiro, Seiki; Sugino, Hiromu.

In: Hepato-gastroenterology, Vol. 52, No. 61, 01.01.2005, p. 60-66.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats

AU - Takamura, Kazuhito

AU - Tsuchida, Kunihiro

AU - Miyake, Hidenori

AU - Tashiro, Seiki

AU - Sugino, Hiromu

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background/Aims: Activin A is an autocrine inhibitor of cell growth in the liver. The biological activity of activin A is mediated by a heteromeric receptor complex. Follistatin (FS) binds to activin and inhibits its biological effects, and acts as a negative regulator of muscle cells. The role of activin receptors during liver regeneration following a hepatectomy has not been fully assessed. This study investigates the mechanism underlying how activin receptors regulate hepatocyte growth, and the effects of intravenous administration of FS during liver regeneration. Methodology: The expression of both activins and activin receptors in the liver after a 70% partial hepatectomy (HT) was assessed by RT-PCR and immunohistochemistry. FS 315 or 288 was infused for different periods of time based on changes in hepatocyte activin receptor expression after HT. Results: Activin receptor expression peaked between 48 and 72 hours after HT. 72 hours after HT, an injection of FS 315 resulted in a more potent stimulation of DNA synthesis and produced a greater increase in body weight compared with the control rats. Conclusions: The expression of activin receptors after peak DNA synthesis might be a key component in the downregulation of DNA synthesis. Intravenous administration of FS 315 might promote liver regeneration and have anabolic actions.

AB - Background/Aims: Activin A is an autocrine inhibitor of cell growth in the liver. The biological activity of activin A is mediated by a heteromeric receptor complex. Follistatin (FS) binds to activin and inhibits its biological effects, and acts as a negative regulator of muscle cells. The role of activin receptors during liver regeneration following a hepatectomy has not been fully assessed. This study investigates the mechanism underlying how activin receptors regulate hepatocyte growth, and the effects of intravenous administration of FS during liver regeneration. Methodology: The expression of both activins and activin receptors in the liver after a 70% partial hepatectomy (HT) was assessed by RT-PCR and immunohistochemistry. FS 315 or 288 was infused for different periods of time based on changes in hepatocyte activin receptor expression after HT. Results: Activin receptor expression peaked between 48 and 72 hours after HT. 72 hours after HT, an injection of FS 315 resulted in a more potent stimulation of DNA synthesis and produced a greater increase in body weight compared with the control rats. Conclusions: The expression of activin receptors after peak DNA synthesis might be a key component in the downregulation of DNA synthesis. Intravenous administration of FS 315 might promote liver regeneration and have anabolic actions.

UR - http://www.scopus.com/inward/record.url?scp=14144256099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14144256099&partnerID=8YFLogxK

M3 - Article

C2 - 15782995

AN - SCOPUS:14144256099

VL - 52

SP - 60

EP - 66

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 61

ER -